2023 Fiscal Year Final Research Report
Development pf novel immune checkpoint inhibition therapy for neuroblastoma focusing on the tumor infiltrating immune cells
| Project/Area Number |
21K08626
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 55010:General surgery and pediatric surgery-related
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | 神経芽腫 / NK細胞 / 腫瘍浸潤リンパ球 / 免疫チェックポイント阻害療法 / 抗腫瘍免疫 |
|---|
| Outline of Final Research Achievements |
For the analysis of antitumr immune reaction to the neuroblastoma induced by the immune checkpoint inhibition therapy, we focused on the tumor infiltrating immune cells induced by the immune checkpoint inhibhtion therapy. Using mouse neuroblastoma model, we applied anti-mouse PD-1/PD-L1 antibody therapy to the neuroblastoma bearing mouse. Then we analyzed the tumor infltrating immune cells.
We found that in tumor which the growth of nodule was effectively suppressed by treatent, infiltration of CD49b+ NK cell and CD69 positive activated CD8 tumor infiltrating lymphocytes (TIL) were effectively promoted.
We concluded that in immune checkpoint inhibition therapy using anti-PD-1/PD-l1antibodies, promotion of the tumor infiltration of NK cell and activated CD8+ TIL is very important. And finding the method of promoting these cells infiltration may induce the establishment of effective and novel immune therapy for neuroblastoma.
|
| Free Research Field |
小児神経芽腫免疫治療
|
| Academic Significance and Societal Importance of the Research Achievements |
臨床データでは、進行神経芽腫に対する免疫チェックポイント阻害療法は、単一の抗体投与では期待されたほどの十分な治療効果が得られていないことが報告された。本研究では、治療効果不良群ではNK細胞及び活性化CD8リンパ球の浸潤が治療効果良好群に比べ少ないことが示され、抗腫瘍免疫反応を十分に得るためには、このNK細胞および活性化CD8リンパ球の浸潤を促進することが重要であることが証明された。NK細胞浸潤及びCD69陽性CD8Tリンパ球の腫瘍浸潤を促進することができれば、有効性の高い新規免疫療法を開発することが可能であること示しており、今後の新規治療開発に有効な知見が得られたといえる。
|
